FINWIRES · TerminalLIVE
FINWIRES

$NVCR

7 stories mentioning NVCRUpdated 30d ago

Every FINWIRES story that references NVCR, newest first.

Wire

NovoCure Says Optune Pax Receives CE Mark for Locally Advanced Pancreatic Cancer Treatment

NovoCure's (NVCR) Optune Pax wearable device has received CE Mark approval in the European Union to treat adult patients with locally advanced pancreatic cancer, in combination with gemcitabine and nab-paclitaxel, the company said Tuesday.The approval was supported by data from a phase 3 trial showing "statistically significant" improvement in overall survival and "significantly extended" time to pain progression, the company said.Optune Pax delivers Tumor Treating Fields, alternating electric fields designed to disrupt cancer cell division without significantly affecting healthy cells, NovoCure said.Shares of NovoCure were 2.6% lower in early Tuesday trading.Price: $15.08, Change: $-0.40, Percent Change: -2.58%

$NVCR
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks fell late Thursday afternoon with the NYSE Healthcare Index dropping 1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.9%.The iShares Biotechnology ETF (IBB) shed 0.3%.In corporate news, Pfizer (PFE) shares dropped 2.5% after the company reaffirmed its fiscal 2026 guidance. The company also said Chief Financial Officer Dave Denton will step down on Aug. 15 after accepting a position in the consumer-goods sector.Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion. Biogen shares fell 1.4%.EnGene (ENGN) shares shed 1.4% after Morgan Stanley downgraded the stock to underweight from equalweight.NovoCure (NVCR) shares tumbled 19% after the company said a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.

$BIIB$ENGN$NVCR$PFE
Sectors

Sector Update: Healthcare Stocks Decline Thursday Afternoon

Healthcare stocks fell Thursday afternoon with the NYSE Healthcare Index decreasing 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) declining 0.8%.The iShares Biotechnology ETF (IBB) shed 0.5%.In corporate news, Pfizer (PFE) shares fell 2.6% after the company said Chief Financial Officer Dave Denton will step down on Aug. 15 after accepting a position in the consumer-goods sector.Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion. Biogen shares fell 1.9%.NovoCure (NVCR) shares dropped 19% after the company said a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.Kardigan (KARD) shares surged 28% to $20.50 in their debut on the Nasdaq. The clinical-stage precision therapeutics company priced its initial public offering of 25 million shares at $16 each. Underwriters were granted a 30-day option to purchase an additional 3.75 million shares.

$BIIB$KARD$NVCR$PFE
Sectors

Sector Update: Healthcare Stocks Advance Premarket Thursday

Healthcare stocks were advancing premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) 0.5% higher.Denali Therapeutics (DNLI) stock was up more than 1% after the company said it has signed an agreement to sell its rare pediatric disease priority review voucher for gross proceeds of $195 million.Pfizer (PFE) shares were down more than 1% after the company said Chief Financial Officer Dave Denton will step down from his position on Aug. 15 after accepting a position outside the pharmaceutical industry in the consumer goods sector.NovoCure (NVCR) stock was down more than 15% after the company said a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.

$DNLI$IBB$NVCR$PFE$XLV
Insider Trading

Novocure Insider Sold Shares Worth $614,635, According to a Recent SEC Filing

Frank X Leonard, Chief Executive Officer, on June 04, 2026, sold 34,273 shares in Novocure (NVCR) for $614,635. Following the Form 4 filing with the SEC, Leonard has control over a total of 459,520 ordinary shares of the company, with 459,520 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1645113/000182287926000004/xslF345X05/primarydocument.xml

$NVCR
Sectors

Sector Update: Health Care Stocks Gain Thursday Afternoon

Health care stocks rose Thursday afternoon with the NYSE Health Care Index climbing 2.5% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 2%.In corporate news, Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose 5.0%.NovoCure (NVCR) shares surged 28% after the company posted Q1 results.

$LLY$NVCR$NVO
Wire

NovoCure Shares Rise Following Q1 Financial Results

NovoCure (NVCR) shares were up more than 24% in Thursday trading after the company posted its Q1 financial results.The pharmaceutical company reported early Thursday a Q1 net loss of $0.62 per diluted share, widening from a loss of $0.31 a year earlier.Analysts polled by FactSet expected a loss of $0.51.Net revenue for the quarter ended March 31 was $174.1 million, up from $155 million a year earlier.Analysts surveyed by FactSet expected $167.8 million.The company said it now expects 2026 total net revenue of $690 million to $710 million, compared with its prior guidance of between $675 million and $705 million. Analysts polled by FactSet expect $694.7 million.Price: $14.81, Change: $+2.88, Percent Change: +24.14%

$NVCR

Track with the FINWIRES app suite

FolioX
FolioX
Track NVCR in your portfolio
WheelAI
WheelAI
Analyze NVCR options with the wheel strategy
StockInsider
StockInsider
See market sentiment on NVCR